Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05159193
Status:
RECRUITING
Last Update Posted:
2024-02-02
First Post:
2021-11-25
Brief Title:
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization Data
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Class:
OTHER
Study ID:
CSPC-DMS-BC-K07
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| CSPC Ouyi Pharmaceutical Co Ltd | INDUSTRY |